Variable | Â | Group | |
---|---|---|---|
Active | Placebo | ||
N | Â | 6 | 6 |
Age | Mean (SD) | 41 (15) | 52 (15) |
Sex | #(%) Male | 4 (67%) | 3 (50%) |
Duration UC | Mean (SD) yrs | 8.9 (9.1) | 9.8 (10.6) |
BMI* | Mean (SD) | 24 (3) | 29 (4) |
Treatment with biologic | #(%) yes | 2 (33%) | 1 (17%) |
Fecal calprotectin | Mean (SD) | 573 (659) | 408 (277) |
Total Mayo score | Mean (SD) | 6.3 (2.0) | 6.7 (1.2) |
 Mayo symptom subscore | Mean (SD) | 4.8 (1.5) | 4.3 (1.0) |
 Mayo endoscopic subscore | Mean (SD) | 1.5 (0.8) | 2.3 (0.5) |
Endoscopic UCEIS^ score | Mean (SD) | 7.0 (1.8) | 8.5 (1.8) |
Histologic Severity Score** | Mean (SD) | 3.4 (1.2) | 4.3 (2.0) |
IBDQ^^ total score | Mean (SD) | 142.8 (16.8) | 120.2 (25.1) |
 IBDQ bowel system subscore | Mean (SD) | 4.2 (0.7) | 4.3 (0.9) |